Antithrombotische Therapie bei akutem Koronarsyndrom und Vorhofflimmern

Abstract

The number of patients with atrial fibrillation (AF) is increasing due to the aging of the population. In addition, the number of patients with AF and an indication for oral anticoagulation (OAC) for the prevention of strokes increases, who are in need for a dual antiplatelet therapy (DAPT) with acetyl salicylic acid (ASA) plus a P2Y₁₂-Inhibitor because of an acute coronary syndrome and/or coronary stent implantation. These patients did receive a triple therapy (TT) for 3–12 months in the past. Triple therapy never has been studied for efficacy or safety, however, the rate of bleeding complications in comparison to OAC or DAPT is significantly higher.

Registries and smaller trials showed that dual therapy with an OAC plus a single platelet inhibitor may be sufficient to prevent strokes and stent thromboses/myocardial infarctions. Four prospective randomized trials involving all four NOACs (Non-Vitamin K oral anticoagulants) approved for stroke prevention in AF have been undertaken. The NOACs plus one antiplatelet agent were tested versus vitamin K-antagonists plus DAPT. In the meantime, the trials involving rivaroxaban (PIONEER AF-PCI), dabigatran (RE-DUAL PCI), apixaban (AUGUSTUS), and edoxaban (ENTRUST-AF-PCI) have been published. The current status is that a NOAC plus a single antiplatelet agent, mostly clopidogrel, is superior to TT with respect to the bleeding complications, without any obvious and statistically significant disadvantage for stroke rates or cardiac ischemic events. The international guidelines already recommend to treat with a NOAC and one antiplatelet agent instead of TT in case the patients bleeding risk is prevailing. Thus, TT seems not to be indicated anymore for most patients with AF and ACS or PCI.

Demografisch bedingt steigt die Zahl der Patienten mit Vorhofflimmern und einer Indikation für eine orale Antikoagulation zur Schlaganfallprävention, die aufgrund eines akuten Koronarsyndroms oder einer perkutanen Koronarintervention eine duale antithrombozytäre Therapie benötigen. Diese Patienten erhielten bislang für 3–12 Monate eine Triple-Therapie. Doch wie ist die Studienlage dazu, welche Bedeutung haben die NOAK und was empfehlen die Leitlinien?

Schlüsselwörter

Antikoagulation - Vorhofflimmern - PCI - akutes Koronarsyndrom - Thrombozytenhemmer

Key words

anticoagulation - atrial fibrillation - PCI - acute coronary syndrome - platelet inhibitors

Publication History

Article published online:
15 July 2020

• Literatur

• 1 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151
• 2 Patel MR, Mahaffey KW, Garg J. et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891
• 3 Granger CB, Alexander JH, McMurray JJ. et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992
• 4 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104
• 5 Gibson CM, Mehran R, Bode C. et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med 2016; 375: 2423-2434
• 6 Cannon CP, Bhatt DL, Oldgren J. et al. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. N Engl J Med 2017; 377: 1513-1524
• 7 Dewilde WJ, Orbans T, Verheugt FW. et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115
• 8 D'Ascenzo F, Taha S, Moretti C. et al. Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. Am J Cardiol 2015; 115: 1185-1193
• 9 Neumann FJ, Sousa-Uva M, Ahlsson A. et al 2018 ESC/EACTS Guidelines on myocardial revascularisation. Eur Heart J 2019; 40: 87-165 . doi:10.1093/eurheartj/ehy394
• 10 Lopes RD, Hong H, Harskamp RE. et al Safety and efficacy of antithrombotic strategies in patients with atrial fibrillation undergoing percutaneous coronary intervention. A network meta-analysis of randomized controlled trials. JAMA Cardio 2019; 4: 747-755 . doi:10.1001/jamacardio.2019.1880
• 11 Vranckx P, Valgimigli M, Eckardt L. et al. Edoxaban-based versus vitamin K antagonist -based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomized, open-label, phase 3b trial. Lancet 2019; 393: 2393-2394
• 12 Lopes RD, Heizer G, Aronson R. et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med 2019; 380: 1509-1524
• 13 January CT, Wann LS, Calkins H. et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for management of patients with atrial fibrillation. JACC 2019; 74: 104-132